Investors: Press Releases

Press Releases

April 14, 2022
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
March 17, 2022
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
March 14, 2022
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
March 10, 2022
NexImmune to Present at the Barclays 2022 Global Healthcare Conference
March 9, 2022
NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
February 17, 2022
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors
February 1, 2022
NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets
January 18, 2022
NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies” 
January 5, 2022
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
December 12, 2021
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
Displaying 11 - 20 of 60